FRENCH-ARRIVE Trial Aims to Confirm 39-Week Labor Induction Reduces Cesarean in Nulliparous Women

The US ARRIVE trial demonstrated that elective labor induction at 39 weeks of gestation could significantly lower cesarean delivery rates in low-risk nulliparous women. However, the generalizability of these findings to diverse healthcare settings outside the US requires validation. High rates of cesarean sections are associated with increased maternal and neonatal risks, highlighting the need for safe and effective strategies to reduce them. The FRENCH-ARRIVE trial addresses this critical gap by seeking to confirm these benefits in a different population and healthcare system.

The FRENCH-ARRIVE trial is a randomized trial conducted in France, comparing elective labor induction at 39 weeks of gestation against expectant management. The study population consists of low-risk nulliparous women. The primary objective is to assess the impact on cesarean delivery rates. Standard institutional induction protocols involve cervical ripening using a cervical Foley catheter or misoprostol, followed by labor augmentation with intravenous oxytocin. This design aims to replicate and validate the findings of the original ARRIVE trial.

The provided abstract details the rationale and design of the FRENCH-ARRIVE trial, but does not present any results or findings from the trial itself. It references the US ARRIVE trial, which reported a significantly lower frequency of cesarean delivery with elective induction at 39 weeks in nulliparous women, with no significant differences in adverse perinatal outcomes. The FRENCH-ARRIVE trial is designed to validate these observations in a different population and healthcare setting. Therefore, specific numerical outcomes, p-values, or effect sizes for the FRENCH-ARRIVE study are not available in this abstract.